Business context and reporting period
MACOM designs and manufactures high-performance semiconductor products for Telecommunications (Telecom), Industrial & Defense (I&D), and Data Center markets. This Form 10-K covers the fiscal year ended October 2, 2020; fiscal 2020 had 53 weeks, including a 14-week first quarter, versus 52 weeks in fiscal 2019. MACOM reports one operating segment.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $530.0 million | $499.7 million |
| Gross profit / margin | $270.2 million / 51.0% | $220.7 million / 44.2% |
| Operating income (loss) | $3.4 million | $(380.4) million |
| Net loss | $(46.1) million | $(383.8) million |
| Basic loss per share | $(0.69) | $(5.84) |
| Cash from operating activities | $171.4 million | $20.7 million |
| Capital expenditures | $17.6 million | $38.0 million |
Fourth-quarter FY2020 revenue was $147.2 million and net income was $17.5 million; the prior-year fourth quarter reported revenue of $112.2 million and net income of $10.5 million. Annual cash and cash equivalents were $129.4 million, short-term investments $203.7 million, and working capital $386.6 million. Long-term debt principal was $666.1 million; the company also had $160.0 million of undrawn revolver capacity, including $50.0 million available without specified financial covenants. The term loans mature in May 2024, while the revolver matures in November 2021. The filing estimates a 1-percentage-point change in interest rates would change annual interest expense by approximately $6.7 million, assuming debt remained constant.
Material changes versus the prior comparable period
- Revenue rose 6.1%, with Telecom up 15.8% to $209.5 million and Data Center up 10.4% to $126.1 million. I&D declined 5.0% to $194.5 million.
- Telecom growth was driven primarily by carrier optical products, including 5G-related products, particularly in Asia. Data Center growth reflected higher sales of high-performance analog products. I&D weakness reflected declines in certain defense programs and legacy product lines.
- Gross margin increased 680 basis points to 51.0%. Management attributed the improvement mainly to lower inventory reserve expenses and the 2019 restructuring’s lower compensation costs and intangible amortization.
- Operating expenses declined substantially: R&D fell 13.5% to $141.3 million and SG&A fell 18.9% to $124.3 million. FY2019 included $264.8 million of impairment charges, compared with none in FY2020.
- Despite positive operating income, MACOM recorded a $46.1 million net loss, including $44.9 million of net other expense. This included $27.4 million of interest expense and $12.9 million of noncash warrant liability expense.
- Operating cash flow increased to $171.4 million, supported in part by reductions in receivables, inventory, prepaid and other assets, and income tax receivable. Cash and investments increased year over year.
Outlook, management commentary, risks and unusual items
- The filing provides no quantitative revenue or earnings guidance. Management identifies 5G and communications-network upgrades, broader I&D applications, and cloud adoption and higher-speed data-center interconnects as potential growth drivers.
- The 2019 Plan, completed in FY2020, reduced the workforce by approximately 250, exited six development facilities, narrowed certain development work, and ended investment in optical modules and subsystems for Data Center applications. Management expects annual expense savings of approximately $50 million, primarily in R&D; it reported no further restructuring costs expected, with remaining charges payable in FY2021.
- COVID-19 had not materially affected FY2020 consolidated operating results, according to management, but its future effects on demand, supply, operations, liquidity, and cash flows remained uncertain.
- Customer and channel concentration is notable: distributors accounted for 45.3% of revenue; Richardson represented 13.5%, and Gateway and Pangaea each represented 11.5%. The top ten customers collectively represented approximately 61% of revenue. Sales outside the U.S. were 59.0% of revenue, with China and Asia Pacific significant markets.
- Key risks include customer order volatility and limited purchase commitments, inventory estimation and obsolescence, semiconductor cyclicality, competition and pricing pressure, reliance on external and sometimes single-source suppliers, export restrictions and trade tensions, and the substantial debt burden. MACOM also cites uncertainty around product development and qualification, including GaN-on-Silicon.
- MACOM reported no material pending litigation at year-end; its Omega Chemical environmental matter had an accrual described as not material, though the ultimate liability could change. The auditor identified inventory excess and obsolescence reserves as a critical audit matter. The financial statement and internal-control audits received unqualified opinions, and management and the auditor concluded internal control over financial reporting was effective.
- Substantially all outstanding warrants were exercised for 850,311 shares on November 11, 2020, after year-end. The FY2020 warrant liability fair-value expense is therefore a notable noncash item in interpreting annual earnings.
Important facts for investors to verify
- Whether growth in Telecom and Data Center can offset continued I&D declines, and how much of FY2020’s revenue increase reflects the extra fiscal week.
- Whether the 51.0% gross margin and approximately $50 million of expected restructuring savings are sustainable, given product mix, manufacturing utilization, and inventory reserves.
- Customer and distributor concentration, especially exposure to major resellers and Asia/China, and any effects of export controls or customer purchasing changes.
- Debt repayment and refinancing capacity, revolver maturity, covenant requirements, and sensitivity to variable interest rates.
- Inventory demand assumptions and any subsequent developments affecting inventory valuation; the auditor specifically highlighted this estimate.
- Post-year-end warrant exercise details and their effect on share count, alongside continuing equity compensation and potential dilution.